The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population, together with additional emerging agents with novel MOAs and a general increase in the use of biologics, will help to drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio) expands physicians’ treatment armamentarium and intensifies market competition. In balance with these factors, the entry of generics for leading branded conventional agents (e.g., Shire’s Lialda), continuing generic erosion of other conventional agents, and additional entries/expanded uses of less expensive biosimilar TNF-alpha inhibitors (e.g., Pfizer’s Inflectra, Amgen’s Amjevita) will constrain the UC market. Indeed, emerging therapies looking to penetrate this market will need to be clearly differentiated from competitors.

QUESTIONS ANSWERED

  • What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
  • How do gastroenterologists perceive biosimilar agents, and what impact have/will these agents have on the UC market?
  • What are KOLs’ insights into current treatment options (e.g., AbbVie/Eisai’s Humira, Pfizer’s Xeljanz)? What factors drive their treatment decisions?
  • What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib, Roche/Genentech’s etrolizumab, Janssen’s Stelara, Celgene’s ozanimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
    • Key Updates
      • November 2019
        • November 2019
      • September 2019
      • May 2019
      • December 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Ulcerative Colitis?
        • What Factors Are Constraining the Market for Ulcerative Colitis?
      • Drug-Class-Specific Trends
        • TNF-Alpha Inhibitors
        • Cell Adhesion Molecule Inhibitors
        • Janus-Activated Kinase Inhibitors
        • Interleukin Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
        • Aminosalicylates
        • Corticosteroids
        • Immunosuppressants
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Key Findings
        • Disease Overview
      • Etiology
        • The Immune Response
      • The Inflammatory Cascade
        • Cytokines
        • Lipid Mediators
        • Cell Adhesion Molecules
        • Janus-Activated Kinase
        • Sphingosine-1-Phosphate Receptors
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Ulcerative Colitis
        • Diagnosed Cases of Ulcerative Colitis
        • Drug-Treated Cases of Ulcerative Colitis
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Aminosalicylates
        • Corticosteroids
        • Immunosuppressants
        • TNF-Alpha Inhibitors
        • CAM Inhibitors
        • JAK Inhibitors
        • Interleukin Inhibitors
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Ulcerative Colitis
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Janus Activated Kinase Inhibitors
        • Cell Adhesion Molecule Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
        • Interleukin Inhibitors
        • DNA-Based Immunomodulators
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Ulcerative Colitis Bibliography

Author(s): Maria Genco, Ph.D; Abey John, MPH

Maria Genco, is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her and in neuroscience from Brandeis University and a in neuroscience from Wellesley College.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis (EU5)

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-&alp...

View Details

Ulcerative Colitis | Access & Reimbursement | Detailed, Expanded Analysis (US)

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (

View Details

Ulcerative Colitis | Emerging Therapies | Xeljanz (Ulcerative Colitis) Launch Tracking Wave 3

Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United S...

View Details

Ulcerative Colitis | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK The moderate to severe ulcerative colitis (UC) therapy market still offers substantial opportunity for companies that can address the remaining unmet need...

View Details